©The Author(s) 2025.
World J Stem Cells. Sep 26, 2025; 17(9): 109715
Published online Sep 26, 2025. doi: 10.4252/wjsc.v17.i9.109715
Published online Sep 26, 2025. doi: 10.4252/wjsc.v17.i9.109715
Figure 3 Gross lung photography of ovalbumin-induced asthmatic mice treated with different dosages of human umbilical cord blood-derived mesenchymal stem cell.
A-E: Gross lung images of a group of control, model, and three different dosages of human umbilical cord blood-derived mesenchymal stem cells treatment. L-D HUC-MSC: Low dosage (1 × 105) of human umbilical cord blood-derived mesenchymal stem cell; M-D HUC-MSC: Medium dosage (2 × 105) of human umbilical cord blood-derived mesenchymal stem cell; H-D HUC-MSC: High dosage (4 × 105) of human umbilical cord blood-derived mesenchymal stem cell.
- Citation: Chen QH, Zheng JY, Zhu YQ, Zhang JY, Lin CY, Zhuang XE, Cheng J, Huang XY. Exploring the critical therapeutic window: Dose-frequency optimization of human umbilical cord mesenchymal stem cells for preclinical asthma treatment. World J Stem Cells 2025; 17(9): 109715
- URL: https://www.wjgnet.com/1948-0210/full/v17/i9/109715.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v17.i9.109715